Valuation: Supernus Pharmaceuticals

Market Cap 1.64B 1.49B 1.38B 1.25B 2.35B 152B 2.47B 16.74B 6.66B 82.91B 6.15B 6.02B 260B P/E 2024
27.4x
P/E 2025 -72.8x
Enterprise Value 1.37B 1.25B 1.15B 1.05B 1.96B 127B 2.06B 14.01B 5.57B 69.37B 5.15B 5.04B 218B EV / Sales 2024
2.38x
EV / Sales 2025 3.59x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day+0.19%
1 week+48.92%
1 month+1.67%
3 months-11.65%
6 months-13.90%
Current year-15.65%
1 month 27.97
Extreme 27.97
44.31
Current year 27.97
Extreme 27.97
59.68
1 year 27.97
Extreme 27.97
59.68
3 years 25.53
Extreme 25.53
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 65 22/12/2005
Director of Finance/CFO 68 23/08/2021
Compliance Officer 63 01/01/2012
Director TitleAgeSince
Director/Board Member 65 22/12/2005
Chairman 81 10/08/2016
Director/Board Member 80 16/11/2010
Date Insider Type Main position Quantity % Market Cap. Importance
2/11/26 Others

Chairman

-212,424 0.3788%
2/11/26 Others

Director

-148,718 0.2652%
2/11/26 Others

Director

-47,667 0.0850%

Financials

2024 2025
Net sales 662M 603M 555M 505M 948M 61.28B 996M 6.76B 2.69B 33.47B 2.48B 2.43B 105B 719M 655M 603M 549M 1.03B 66.58B 1.08B 7.34B 2.92B 36.36B 2.7B 2.64B 114B
Net income 73.86M 67.28M 61.99M 56.39M 106M 6.84B 111M 754M 300M 3.74B 277M 271M 11.72B -38.55M -35.11M -32.35M -29.43M -55.21M -3.57B -58.03M -394M -157M -1.95B -145M -142M -6.12B
Net Debt -419M -382M -352M -320M -601M -38.83B -631M -4.28B -1.7B -21.21B -1.57B -1.54B -66.56B -268M -244M -225M -204M -383M -24.79B -403M -2.73B -1.09B -13.54B -1B -983M -42.49B
Projected Income Statement - Annual - Supernus Pharmaceuticals
Logo Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Supernus Pharmaceuticals
  1. Stock Market
  2. Stocks
  3. SUPN Stock